Statewide coordinated STEMI approach deemed successful

June 5, 2012 in Cardiology

Statewide coordinated STEMI approach deemed successful

A statewide coordinated effort across hospitals and emergency medical service providers to transport patients with ST-segment elevation myocardial infarction to hospitals providing percutaneous coronary intervention has resulted in improved outcomes, according to a study published online June 4 in Circulation.

(HealthDay) -- A statewide coordinated effort across hospitals and emergency medical service (EMS) providers to transport patients with ST-segment elevation myocardial infarction (STEMI) to hospitals providing percutaneous coronary intervention (PCI) has resulted in improved outcomes, according to a study published online June 4 in Circulation.

James G. Jollis, M.D., from Duke University in Durham, N.C., and colleagues analyzed performance data from the 119 North Carolina hospitals participating in a coordinated plan to treat STEMI patients according to presentation.

The researchers found that, between July 2008 and December 2009, 6,841 patients with STEMI were treated (median age, 59 years; 30 percent women). Of the treated patients, 3,907 presented directly to 21 PCI hospitals and 2,933 were transferred from a total of 98 non-PCI hospitals. Over the period analyzed, the rate of patients not receiving reperfusion decreased significantly from 5.4 to 4.0 percent. Treatment times improved substantially for patients requiring hospital transfer. For patients presenting directly to PCI hospitals, the median door-to-device times declined significantly, from 64 to 59 minutes, with EMS-transported patients the most likely to reach door-to-device treatment goals within 90 minutes (91 percent). Mortality was significantly lower for patients treated within guideline goals (2.2 percent, versus 5.7 percent for those exceeding ).

"By extending regional coordination to an entire state, rapid diagnosis and treatment of STEMI has become an established standard of care independent of health care setting or geographic location," the authors write.

Several authors disclosed to medical device and pharmaceutical companies, including Phillips, Sanofi-Aventis, and the Medtronic Foundation, all of which funded the study.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Journal reference: Circulation search and more info website

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Costs to treat stroke in America may double by 2030

Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.

Cardiology created 4 hours ago | popularity not rated yet | comments 0

New blood-thinner measures may cut medication errors

Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...

Cardiology created 6 hours ago | popularity not rated yet | comments 0

Registry questions superiority of bivalirudin over heparin

Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...

Cardiology created 6 hours ago | popularity not rated yet | comments 0

Study shows low rate of late lumen loss with bioresorbable DESolve device

The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial ...

Cardiology created 6 hours ago | popularity not rated yet | comments 0

Biodegradable stent proves non-inferior to drug-eluting stent

The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...

Cardiology created 22 hours ago | popularity 5 / 5 (1) | comments 0


Novel approach for influenza vaccination shows promise in early animal testing

A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...

Brain can be trained in compassion, study shows

Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.

SARS-like virus claims new life in Saudi

A man who had contracted the coronavirus has died in Saudi Arabia, raising the death toll in the kingdom from the SARS-like virus to 17, the health ministry announced on its website on Wednesday.

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Good marriage can buffer effects of dad's depression on young children

What effect does a father's depression have on his young son or daughter? When fathers report a high level of emotional intimacy in their marriage, their children benefit, said a University of Illinois study.

Hospitals profit when patients develop bloodstream infections

Johns Hopkins researchers report that hospitals may be reaping enormous income for patients whose hospital stays are complicated by preventable bloodstream infections contracted in their intensive care units.